These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases. Yamashita S; Chun YS; Kopetz SE; Maru D; Conrad C; Aloia TA; Vauthey JN Ann Surg; 2020 Dec; 272(6):1080-1085. PubMed ID: 28379870 [TBL] [Abstract][Full Text] [Related]
8. Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation. Kawaguchi Y; Lillemoe HA; Panettieri E; Chun YS; Tzeng CD; Aloia TA; Kopetz S; Vauthey JN J Am Coll Surg; 2019 Sep; 229(3):286-294.e1. PubMed ID: 31054911 [TBL] [Abstract][Full Text] [Related]
9. Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases. Chun YS; Passot G; Yamashita S; Nusrat M; Katsonis P; Loree JM; Conrad C; Tzeng CD; Xiao L; Aloia TA; Eng C; Kopetz SE; Lichtarge O; Vauthey JN Ann Surg; 2019 May; 269(5):917-923. PubMed ID: 28767562 [TBL] [Abstract][Full Text] [Related]
10. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases. Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557 [TBL] [Abstract][Full Text] [Related]
11. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. Shindoh J; Loyer EM; Kopetz S; Boonsirikamchai P; Maru DM; Chun YS; Zimmitti G; Curley SA; Charnsangavej C; Aloia TA; Vauthey JN J Clin Oncol; 2012 Dec; 30(36):4566-72. PubMed ID: 23150701 [TBL] [Abstract][Full Text] [Related]
12. Mutation Status of Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662 [TBL] [Abstract][Full Text] [Related]
13. CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases. Stremitzer S; Stift J; Graf A; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T Ann Surg Oncol; 2015 Apr; 22(4):1315-23. PubMed ID: 25323471 [TBL] [Abstract][Full Text] [Related]
14. Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. Frankel TL; Vakiani E; Nathan H; DeMatteo RP; Kingham TP; Allen PJ; Jarnagin WR; Kemeny NE; Solit DB; D'Angelica MI Cancer; 2017 Feb; 123(4):568-575. PubMed ID: 27737491 [TBL] [Abstract][Full Text] [Related]
15. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288 [TBL] [Abstract][Full Text] [Related]
16. The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS. Amikura K; Akagi K; Ogura T; Takahashi A; Sakamoto H J Surg Oncol; 2018 Mar; 117(4):745-755. PubMed ID: 29194647 [TBL] [Abstract][Full Text] [Related]
17. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion. Shindoh J; Nishioka Y; Yoshioka R; Sugawara T; Sakamoto Y; Hasegawa K; Hashimoto M; Kokudo N Ann Surg Oncol; 2016 Jun; 23(6):1890-6. PubMed ID: 26786089 [TBL] [Abstract][Full Text] [Related]
18. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Kemeny NE; Chou JF; Capanu M; Gewirtz AN; Cercek A; Kingham TP; Jarnagin WR; Fong YC; DeMatteo RP; Allen PJ; Shia J; Ang C; Vakiani E; D'Angelica MI Cancer; 2014 Dec; 120(24):3965-71. PubMed ID: 25155157 [TBL] [Abstract][Full Text] [Related]
19. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801). Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C Oncology; 2014; 87(1):7-20. PubMed ID: 24968756 [TBL] [Abstract][Full Text] [Related]
20. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]